FDA Accepts Genentech’s Fenebrutinib NDA for Priority Review in MS…

Event summary

FDA accepted Genentech’s NDA for fenebrutinib under priority review for relapsing and primary progressive multiple sclerosis (RMS, PPMS).
Fenebrutinib is the first BTK inhibitor to receive FDA filing acceptance for both RMS and PPMS.
Phase III studies showed fenebrutinib reduced annualized relapse rate by 51.1% and 58.5% in RMS studies compared to teriflunomide.
Fenebrutinib met non-inferiority compared to Ocrevus in reducing disability progression in PPMS.

The big picture

Genentech’s fenebrutinib represents a strategic shift in the multiple sclerosis treatment landscape, offering the first oral, high-efficacy therapy for both relapsing and progressive forms of the disease. This development comes at a time when over a third of MS patients still receive lower-efficacy treatments, highlighting the unmet need in the market. The acceptance of the NDA under priority review underscores the potential of fenebrutinib to address both acute inflammation and chronic disability progression, positioning Genentech to compete directly with Roche’s Ocrevus.

What we're watching

Regulatory Dynamics: The pace at which the FDA will review fenebrutinib’s NDA and potential approval timeline.
Market Positioning: Whether fenebrutinib can capture market share from Ocrevus, the current standard of care for PPMS.
Clinical Efficacy: The long-term efficacy and safety profile of fenebrutinib in real-world settings post-approval.